Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of RBM10 gene

A gene and application technology, applied in the application field of RBM10 gene, can solve the problems such as not getting significant benefits

Pending Publication Date: 2022-02-18
SHENZHEN CHIPSCREEN BIOSCIENCES CO LTD +1
View PDF16 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0008] In addition to anti-angiogenic drugs, other mechanism-targeted therapy or immunotherapy has also been developed in platinum-refractory / drug-resistant recurrent ovarian cancer, such as polyadenosine diphosphate-ribose polymerase (PARP) inhibitors such as Olapa Niraparib, niraparib, has a clear effect on ovarian cancer patients with BRCA mutations, but has not yet achieved significant benefit in most platinum-refractory / drug-resistant relapsed ovarian cancer patients without BRCA mutations

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of RBM10 gene
  • Application of RBM10 gene

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0059] Example 1: Phase Ib clinical trial of Cioronib monotherapy for relapsed and refractory ovarian cancer

[0060] Test drug: Cioroni capsules, specifications: 5mg, 25mg. Produced by Shenzhen Microchip Biotechnology Co., Ltd.

[0061] Dosing regimen: Cioroni capsules are administered at 50 mg / day, QD (no adjustment for body weight or body surface area). Take every morning on an empty stomach with water, swallowing the whole capsule whole. Continuous administration for 28 days constitutes a treatment cycle, and there is no interval between each treatment cycle.

[0062] Number of cases: 25 cases were enrolled, of which 23 cases had curative effect evaluation.

[0063] standard constrain:

[0064] 1. Age ≥ 18 years old, ≤ 70 years old, female;

[0065] 2. Epithelial ovarian cancer, fallopian tube cancer or primary peritoneal cancer confirmed by histology;

[0066] 3. Subjects need to have received platinum-based chemotherapy regimens, that is,

[0067] a) Platinum-resi...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to application of an RBM10 gene. The invention discloses a biomarker for evaluating the curative effect of Chiauranib or guiding the medication of Chiauranib or predicting the treatment effect of ovarian cancer. The biomarker is an RBM10 gene or mRNA thereof or a protein or a protein fragment coded by the RBM10 gene. According to the application, the progression-free survival (PFS) of a patient is taken as a curative effect index, the relevance between RBM10 gene variation and the curative effect of Chiauranib is verified, the detection of RBM10 gene mutation information can guide the clinical medication of Chiauranib and evaluate the curative effect of Chiauranib on tumor treatment, and Chiauranib is particularly suitable for recurrent and advanced ovarian cancer.

Description

[0001] This application claims the priority of the application with the application date of July 29, 2020, the application number 202010744602.3, and the invention title "Use of RBM10 Gene". The entire content of said application is hereby incorporated in its entirety. technical field [0002] The invention relates to the field of medicine technology, in particular to the application of RBM10 gene. Background technique [0003] Ovarian cancer ranks third among gynecological malignancies, and its mortality rate ranks first, and its incidence rate is increasing year by year. Patients with ovarian cancer undergo ideal cytoreductive surgery (residual tumor lesions <1cm) and adjuvant systemic chemotherapy with platinum and paclitaxel. Most patients can achieve complete remission (CR), but 60%-70% of patients will recover after treatment. Recurrence occurs. Relapsed patients are less effective for re-chemotherapy: Platinum-sensitive relapsed patients have an effective rate of...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C12Q1/6886G01N33/574A61K31/47A61P35/00
CPCC12Q1/6886G01N33/57484G01N33/57449A61K31/47A61P35/00C12Q2600/106C12Q2600/156G01N33/574C12Q1/68
Inventor 山松潘德思乔伟姚何周游宁志强
Owner SHENZHEN CHIPSCREEN BIOSCIENCES CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com